

MONOCLONAL ANTIBODIES

and Fc fusion proteins for therapeutic use

DISTRIBUTION OF INTERNATIONAL NONPROPRIETARY NAMES BY INDICATION

SOLID TUMORS

Lung cancer	bevacizumab nivolumab necitumumab
Colorectal cancer	bevacizumab cetuximab panitumumab afibercept
Breast cancer	trastuzumab bevacizumab pertuzumab trastuzumab entansine
Gastric cancer	trastuzumab ramucirumab
Head and neck cancer	cetuximab
Ovarian cancer	bevacizumab
Fallopian tube cancer	bevacizumab
Cervical cancer	bevacizumab
Kidney cancer	bevacizumab nivolumab
Melanoma	ipilimumab nivolumab pembrolizumab
Neuroblastoma	dinutuximab
Malignant ascites	catumaxomab
Bone metastasis	denosumab

HAEMOSTASIS AND THROMBOSIS

Haemophilia A	efmoroctocog α
Haemophilia B	eftrenonacog α
Reversal of Dabigatran	idarucizumab

CARDIOLOGY

Unstable angina Percutaneous coronary intervention	abciximab
--	-----------

GENETIC DISEASES

Cryopyrinopathies	canakinumab
Atypical hemolytic uremic syndrome	eculizumab
Familial hypercholesterolemia	evolocumab alirocumab

PNEUMOLOGY

Allergic asthma	omalizumab
Severe eosinophilic asthma	mepolizumab

HAEMATOLOGIC DISEASES

Hodgkin's lymphoma	brentuximab vedotin
Non-hodgkin's lymphoma	rituximab ibratumomab tiuxetan brentuximab vedotin inotuzumab ozogamicine
Chronic lymphocytic leukaemia	rituximab alemtuzumab ofatumumab obinutuzumab
Acute lymphocytic leukaemia	blinatumomab inotuzumab ozogamicine
Acute myeloid leukaemia	gemtuzumab ozogamicine
Multiple myeloma	daratumumab elotuzumab
Castleman's disease	siltuximab
Idiopathic thrombocytopenic purpura	romiplostim
Paroxysmal nocturnal haemoglobinuria	eculizumab

GASTROENTEROLOGY

Crohn's disease	infliximab adalimumab vedolizumab
Ulcerative colitis	infliximab adalimumab golimumab vedolizumab

DERMATOLOGY

Psoriasis	etanercept infliximab adalimumab ustekinumab secukinumab
Chronic spontaneous urticaria	omalizumab

OPHTHALMOLOGY

Age related macular degeneration	ranibizumab afibercept bevacizumab
Macular edema	ranibizumab afibercept
Myopic choroidal neovascularization	ranibizumab afibercept

RHUMATOLOGY

Osteoporosis	denosumab
Rheumatoid arthritis	etanercept infliximab adalimumab rituximab abatacept tocilizumab certolizumab pegol golimumab
Psoriatic arthritis	etanercept adalimumab infliximab golimumab ustekinumab certolizumab pegol secukinumab
Ankylosing spondylitis	infliximab etanercept adalimumab golimumab certolizumab pegol secukinumab
Juvenile arthritis	etanercept adalimumab abatacept tocilizumab canakinumab
Gouty arthritis	canakinumab

NEUROLOGY

Multiple sclerosis	natalizumab alemtuzumab daclizumab
--------------------	--

TRANSPLANTATION

Transplant rejection	basiliximab belatacept
Graft versus host disease	inolimomab

IMMUNOLOGY

Systemic lupus erythematosus	belimumab
------------------------------	-----------

INFECTIOUS DISEASES

Prevention of respiratory syncytial virus infection	palivizumab
Anthrax infection	raxibacumab